Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
64x Bio logo — Enabling next generation medicines.

64x Bio

Enabling next generation medicines.

Founded 2018 United States Brisbane, United States 21 employees Series A Total: $59.50M Biopharma, Biotechnology +2

General Information

Company Name 64x Bio
Founded Year 2018
Location United States Brisbane, United States
Employees 21
Industries Biopharma, Biotechnology, Life Sciences +1
Funding Stage Series A
Business Model B2B, Platform, API
Revenue Model Licensing, Service Fee, Product Sales
Social

BounceWatch is an independent company data service, not affiliated with 64x Bio. To contact 64x Bio, visit 64xbio.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does 64x Bio compare?

A PDF of 64x Bio and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting 64x Bio soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About 64x Bio

64x Bio, founded in 2018 and headquartered in the United States, positions itself at the forefront of the life sciences industry with its mission of "Enabling next generation medicines." The company provides a sophisticated platform and product suite specifically tailored for advanced therapeutics, capturing attention in the intersecting sectors of Biopharma, Biotechnology, Life Sciences, and Pharmaceuticals.

The company secured a substantial $55.00M Series A investment on 19 January 2022, which underscores investor confidence in its growth potential and innovative capabilities. This financing round included prominent investors such as BoxGroup, First Round Capital, Liquid 2 Ventures, and Northpond Ventures, among others. The involvement of seasoned investors like Michael Chambers, Chris Gibson, and Milad Alucozai further validates the company's strategic direction and technological promise.

Business keywords: Mammalian Cell Line Discovery, High Throughput Screening, Computational Design Loop, Viral Vector Manufacturing, Cell and Gene Therapy, Gene Therapy, Synthetic Biology, Genome Engineering, Functional Genomics, Biopharmaceutical Innovation, Advanced Therapeutics, Biomanufacturing Optimization, Therapeutic Cell Lines, Biotechnology R&D

Services & Products

Engineering high yield cell lines
Optimizing production technologies
Gene therapy manufacturing
Cell line licensing
Therapeutic system design

Target Customers

Biopharmaceutical Companies Contract Development and Manufacturing Organizations (CDMOs) Biotech Researchers Gene Therapy Developers Cell and Gene Therapy Companies

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Series A $55.00M 10
BoxGroup First Round Capital Liquid 2 Ventures
BoxGroup, First Round Capital +8
19 Jan 2022
Seed Round $4.50M -
16 Nov 2020
Seed Round Undisclosed -
20 Aug 2018

64x Bio Alternatives & Competitors

View All Alternatives
64x Bio vs
ProBio
ProBio United States

Manufacturing Life-Changing Therapies

Series C
246 employees
Biopharma, Biotechnology
64x Bio vs
Octant
Octant United States

Developing synthetic technology and applying next-generation DNA sequencing, gene synthesis, and gen...

Series B
69 employees
Biotechnology, Life Sciences
64x Bio vs
GenScript ProBio
GenScript ProBio

A comprehensive R&D and production platform offering complete solutions for cell and gene therapy, v...

Series C
1001-5000 employees
Biopharma, Pharmaceutical
Also compare with: 64x Bio vs NewBiologix NewBiologix 64x Bio vs Dyno Therapeutics Dyno Therapeutics 64x Bio vs Berkeley Lights Berkeley Lights View all alternatives

FAQ About 64x Bio

Enabling next generation medicines.
64x Bio was founded in 2018.
64x Bio is headquartered in Brisbane, United States.
64x Bio operates in Biopharma, Biotechnology, Life Sciences and Pharmaceutical. Its work centres on Mammalian Cell Line Discovery, High Throughput Screening, Computational Design Loop and Viral Vector Manufacturing. Its customers include Biopharmaceutical Companies, Contract Development and Manufacturing Organizations (CDMOs) and Biotech Researchers.
64x Bio has a B2B, Platform and API business model. Its revenue comes from Licensing, Service Fee and Product Sales.
64x Bio has approximately 21 employees.
64x Bio has completed 3 funding rounds, raising a total of $59.50M. The latest funding stage is Series A.
64x Bio offers: Engineering high yield cell lines, Optimizing production technologies, Gene therapy manufacturing, Cell line licensing, Therapeutic system design.
Top alternatives and competitors to 64x Bio include ProBio, Octant, GenScript ProBio, Affinia Therapeutics, NewBiologix. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
64x Bio and ProBio are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for 64x Bio, https://bouncewatch.com/company/64x-bio, updated 16 June 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes